KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Preferred Equity: 2015-2017

Historic Other Preferred Equity for Teva Pharmaceutical Industries (TEVA) over the last 2 years, with Sep 2017 value amounting to $3.6 billion.

  • Teva Pharmaceutical Industries' Other Preferred Equity changed negligibly% to $3.6 billion in Q3 2017 from the same period last year, while for Sep 2017 it was $3.6 billion, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $3.6 billion for FY2016, which is 10.00% up from last year.
  • According to the latest figures from Q3 2017, Teva Pharmaceutical Industries' Other Preferred Equity is $3.6 billion, which was down 0.00% from $3.6 billion recorded in Q2 2017.
  • Over the past 5 years, Teva Pharmaceutical Industries' Other Preferred Equity peaked at $3.6 billion during Q1 2016, and registered a low of $3.3 billion during Q4 2015.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Other Preferred Equity value was $3.6 billion (recorded in 2017), while the average stood at $3.6 billion.
  • Data for Teva Pharmaceutical Industries' Other Preferred Equity shows a peak YoY increased of 10.00% (in 2016) over the last 5 years.
  • Over the past 3 years, Teva Pharmaceutical Industries' Other Preferred Equity (Quarterly) stood at $3.3 billion in 2015, then increased by 10.00% to $3.6 billion in 2016, then remained steady at $3.6 billion in 2017.
  • Its Other Preferred Equity was $3.6 billion in Q3 2017, compared to $3.6 billion in Q2 2017 and $3.6 billion in Q1 2017.